Hypoparathyroidism Natural History Study
Key facts
- Who runs it
- Columbia University
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 106 people, planned
- Started
- 25 Aug 2022
- Expected to end
- Dec 2026
- Type of study
- Observational, 2 groups
- Record updated
- 16 December 2025
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- An understanding, ability and willingness to fully comply with study procedures and restrictions
- Ability to voluntarily provide written, signed and dated informed consent as applicable to participate in the study
- Male or female ≥18 years of age with HPT. All HPT sub-types are eligible, including surgical (HPT-S) and nonsurgical (HPT-NS) HPT: autoimmune, genetic (including but not limited to: DiGeorge syndrome, autoimmune polyendocrine syndrome type 1, hypoparathyroidism sensorineural deafness and renal disease syndrome, Kearns-Sayre syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes [MELAS] syndrome, mitochondrial trifunctional protein [MTP] deficiency syndrome, Kenny-Caffey syndrome, Sanjad-Sakati syndrome, autosomal dominant hypocalcemia), infiltrative (granulomatous), mineral deposition (copper, iron), metastatic, radiation and idiopathic HPT
- Diagnosis of HPT established based on historic hypocalcemia in the setting of inappropriately low serum PTH levels on two occasions
- All treatment regimens are permitted, including but not limited to conventional management with calcium (e.g. calcium citrate, calcium carbonate, etc), active vitamin D (calcitriol, alfacalcidol), parent vitamin D, magnesium, phosphate binders and thiazides. Use of PTH-like drugs are permitted
Who cannot take part
- Functional HPT
- Transient HPT
- Pseudohypoparathyroidism
- Pregnancy
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Hypoparathyroidism
This trial is currently available in United States.
- Columbia University Medical Center-Harkness PavillionNew York, United StatesContact: Noelle TexeiraTaking people
About the trial
What the trial wants to find out
This is a prospective three-year natural history study of adults with hypoparathyroidism. The goal is to monitor patients with hypoparathyroidism to define end-organ damage in the context of the disease.
Read full original descriptionShow less
The study objectives are to:
1. Build a prospective cohort of patients to study HPT-associated end-organ damage. 2. Determine end-organ physiologic consequences of HPT. 3. Elucidate determinants of HPT-associated end-organ damage.
Funding Source - FDA OOPD
The 2 groups in the trial
- Hypoparathyroidism Subjects
Patients who have the disease hypoparathyroidism, who are being followed to monitor various aspects of the disease over time. No interventions.
- Control Subjects
Healthy individuals to be followed to compare to hypoparathyroidism patients
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Advancing Product Development for Hypoparathyroidism: A Prospective Natural History Study of the Clinical Outcomes and Regulation of Disordered Mineral Metabolism
- Criteria questions
- Built from NCT05793853, who can take part
- Record updated
- 16 December 2025